Article
NeurologyLive Friday 5 — June 26, 2020
Author(s):
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: The Road to Accessible Biomarkers for Alzheimer Disease
Biomarkers in the cerebrospinal fluid and blood could hold the key to early diagnosis of Alzheimer disease, featuring insight from Rebecca M. Edelmayer, PhD, director of scientific engagement at the Alzheimer’s Association.
2: Peer Exchange: First-Line Therapies for Relapsing Multiple Sclerosis
Fred Lublin, MD; Wallace Brownlee, MBChB, PhD, FRACP; Patricia K. Coyle, MD; and Sven Meuth, MD, PhD, discuss their approach to first-line therapy and the primary therapies they use based on approval status in the United States and Europe.
3: Podcast: Masculinity and Multiple Sclerosis
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Bryan Davis, PsyD, MS, clinical health psychology fellow, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic.
4: FDA Approves Fenfluramine for Treatment of Dravet Syndrome
Fintepla, marketed by Zogenix, will be available for prescription for the rare pediatric epilepsy syndrome beginning in July 2020 through a REMS program.
5: Q&A: Adapting Specialty Care During the Pandemic
In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.
